Siegfried
Address: Untere Bruehlstrasse 4, Zofingen, CH-4800About Us
The Siegfried Group is a global life sciences company, headquartered in Switzerland, with facilities located in Switzerland, the USA, Malta, China, Germany and France.
In 2019, the company achieved net sales of CHF 833.5 million and currently employs approximately 2500 people. Siegfried Holding AG is publicly listed on the Swiss Stock Exchange in Zurich (SIX: SFZN).
Siegfried is active in primary and secondary drug manufacturing. The company develops and manufactures active pharmaceutical ingredients for pharmaceutical clients with R&D programs, related intermediates and controlled substances. Siegfried also offers development and production of finished dosage forms, including sterile fillings.
Sectors
- Contract Manufacturing
Categories
- Active Pharmaceutical Ingredients
- Chemical Intermediates
- Formulation Development
- Multi Layer Tablet Technology
- Finished Dosage
- Solid Dose Formulations
- Sterile Formulations
- High Potency API's
- Chemical Synthesis-cGMP
- Controlled Status Products
- Containment Facilities
- Micronisation
- Particle Size Reduction
- Parenterals
- Vials-Filling Services
- Cartridge-Filling
- Ampoules-Filling Services
- Syringe Filling
- Aseptic Processing
- Terminal Sterilization
- Clinical Trial Manufacturing
News
Siegfried to acquire high-quality small molecules drug substance capacity in the US
Siegfried (SIX: SFZN), a leading global Contract Development and Manufacturing Organization (CDMO) for the pharmaceutical industry, has signed binding agreements with an affiliate of SK Capital Partners to acquire the drug substance business of the Noramco Group and Extractas Bioscience. The acquired businesses include three high-quality small molecules drug substances sites with approximately 400 employees.
Siegfried to Acquire Two Pharmaceutical Manufacturing Sites from Novartis in Spain
Siegfried (SIX: SFZN) has signed binding agreements with Novartis regarding the acquisition of two pharmaceutical manufacturing sites in Spain. With this acquisition, Siegfried will significantly enhance its global production network in terms of capacity and technological capabilities and will achieve the targeted critical size in the field of drug products (finished dosage forms), thus creating further potential for profitable growth in the highly attractive CDMO market. Subject to customary closing conditions, the transaction is expected to close at the end of 2020.
Dr. Wolfgang Wienand, Chief Executive Officer of Siegfried: "This acquisition is perfectly in line with our corporate strategy EVOLVE and represents another major step towards our vision to create one of the most competitive integrated global networks in the CDMO industry. The two new manufacturing sites are ideal complements to our current activities in the field of drug products. They will help us to achieve the necessary critical size in our drug product network and enable us to apply our successful network strategy not only in the field of drug substances but also for drug products. Thanks to the significant additional capacity and the enhanced technological capabilities, we will become an even more attractive strategic partner for the pharmaceutical industry and create further potential for profitable growth. Now, my team and I look forward to our close cooperation with Novartis."
Keryx Biopharmaceuticals, Inc. and Siegfried enter into a Master Manufacturing Services and Supply Agreement
Source: The Partnership Tree | https://www.pharmaservicesdirectory.com